Dr Douglas Clarkson reports on the treatment of wet AMD patients with epimacular brachytherapy, a promising and cost effective technique that is under trial at present
The emergence of the standard treatment for wet age-related macular degeneration (AMD) as intraocular injections of the anti-VEGF drug Lucentis (ranibizumab) presents a significant increase in current and anticipated drug expenditure.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here